Ipca Laboratories Limited: Value Pick Stock April 2020
Ipca Laboratories Limited (IPCA) is a fully-integrated Indian pharmaceutical company manufacturing and marketing over 350 formulations and 80 Active Pharmaceutical Ingredients (APIs) covering various therapeutic segments.
Ipca Laboratories Limited: Profile
Ipca Laboratories was founded by a group of businessmen and medical professionals in the year 1949 under the name of The Indian Pharmaceutical Combine Association Limited.
The name of the organization was changed to Ipca Laboratories Ltd in the year 1964 and again the name was changed to Ipca Laboratories Private Limited in the year 1966.
In the year 1975, the management of the company was taken over by M.R. Chandurkar and P.C. Godha. The corporate office of the company is at Kandivali (Mumbai)
Ipca Laboratories: Business Activities
The key activities of the company are to produce and market drugs and pharmaceuticals.
It produces Acetylthiophene, Theobromine, and P-Bromo Toluene as Active Pharmaceutical Ingredients (APIs)
The Company is one of the world’s largest manufacturers of APIs – Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Furosemide (diuretic), Hydroxychloroquine Sulphate (NSAID), Metoprolol Succinate (anti-hypertensive), Metoprolol Tartrate (anti-hypertensive) and Pyrantel Salts (anthelmintic) – other than being one of the biggest suppliers of these APIs around the world.
The Company has emerged as one of India’s top exporters of APIs with nearly 25 percent of the turnover coming from APIs.
These are created directly from the basic stage at manufacturing facilities inspected by the world’s most discerning drug regulatory authorities such as US-FDA, EDQM-Europe, UK-MHRA, WHO-Geneva and many more.
Ipca Laboratories Limited is a “therapy leader” in India for anti-malarials with a market share of more than 34 percent with a fast-growing presence in the global market as well. The company also leads to DMARDs (Disease-Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis.
Strong Leadership:
For more than 60 years, Ipca has been partnering healthcare globally in over 120 countries including Cambodia, Kazakhstan, Kenya, Mauritius, Myanmar, Nigeria, Oman, Russia, Sri Lanka, Sudan, Tanzania, Ukraine, Vietnam and Yemen and in markets as diverse as Africa, Asia, Australia, Europe, and the US.
Awards:
In 2004, Forbes selected Ipca Laboratories, for the 2nd consecutive year as one among the first 200 Best under a Billion Company in Asia.
Ipca was awarded as – Among the 100 Best Companies to Work in India 2010 – in a study conducted by Great Place to Work India (in collaboration with The Economic Times)
Manufacturing Units:
The Company has 17 manufacturing units in India manufacturing APIs and formulations for the world market.
Client List:
The Company’s worldwide client list includes global pharmaceutical giants like AstraZeneca, Merck, GlaxoSmithKline, Roche, and Sanofi Aventis; most of whom Ipca Laboratories have been partnering over the years.
Listed On:
The shares of Ipca Laboratories Limited are presently listed at Bombay Stock Exchange (BSE); CODE 524494 and National Stock Exchange (NSE) as IPCALAB
Stock Info: Ipca Laboratories
Share Holding Pattern
Financials: Ipca Laboratories
Conclusion
For more than sixty years, Ipca Laboratories Limited has been partnering healthcare globally in over 120 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.
Promoters of the company are having more than 46 percent stake with 0 percent pledge shares.
Along with this, some of the top institutions like Lavender Investments Limited, HDFC Trustee Company Ltd, ICICI Prudential, Abu Dhabi Investment Authority – Behave, DSP Small Cap Fund, UTI, Mirae Asset Emerging Bluechip Fund, and IDFC Sterling Value Fund is having more than 1 percent stake in the company.
On the technical front, Ipca Laboratories is trading well above its 50 EMA (1348) and 200 EMA (1150) on the daily chart.
Keeping the above-listed factors in mind, Ipca Laboratories Limited looks good at INR 1385. Finblab recommends investing in the stock in a staggered manner for medium to long term.
Value Pick Stock: March 2020
HDFC Life Insurance Company
Disclaimer: The contents and data presented here are just for your information & personal use only. While much effort is made to provide the information, I (Vishal Dalwadi) or “FinBlab” do not guarantee the accuracy, correctness, completeness or reliability of any information or data displayed herein and shall not be held responsible.
